Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035. ‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight. Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.

Om Podcasten

What if we spent more time thinking about solutions rather than problems? Are you looking for more positive news? World Changing Ideas travels around the globe to find the leaders, experts and activists who are dreaming big and working to change the world for the better. With a focus on the environment, social justice and innovation, these are stories that will get you thinking. World-changing ideas come in all shapes and sizes. Join the conversation with solutions journalist and filmmaker Amelia Hemphill.